India's Alkem faces new FDA concerns

FDA sign

India’s Alkem Laboratories, already dealing with concerns raised by EU regulators over one plant, now says the FDA has issued more than a dozen observations at one of its other key facilities.

In a filing with the Bombay Stock Exchange, Alkem reported that a two-week FDA inspection at its plant in Daman concluded on Thursday with a Form 483 that listed 13 observations. Alkem gave no details of the findings but simply said that it would put together a detailed response “with adequate corrective and preventive measures to address the US FDA Observations” and send it to the FDA within the agency’s stipulated timeframe.

Earlier this year, the U.K.'s Medicines and Healthcare Products Regulatory Agency said an inspection of the company's Alkem’s Taloja site found instances of data falsification. In that case, Alkem also said it would respond to regulators' concerns as the MHRA requested.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The FDA has had issues with Alkem before. In 2014, it sent U.S. marshals into a warehouse in Ohio to seize more than $11 million worth of drugs made by Alkem subsidiary Ascend Laboratories, including skin creams, ear drops and a treatment for inflamed hemorrhoids. It accused Alkem Laboratories of selling the products in the U.S. without ever getting approvals for them and said it had warned the drugmaker it needed approvals following an inspection.

- here’s the BSE filing

Related Articles:
FDA sends marshals in to seize drugs from unit of Alkem
India's Alkem to respond to European data fraud probe

Suggested Articles

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.